Creative Commons source reading · Multiple sclerosis and neuroimmunology
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Edgar Carnero Contentti; Jorge Correale
Originally published in Journal of neuroinflammation · 2021-09-16
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Neuromyelitis optica (NMO) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) characterized by acute optic neuritis (ON) and transverse myelitis (TM). NMO is caused by a pathogenic serum IgG antibody against the water channel aquoporin 4 (AQP4) in the majority of patients. AQP4-antibody (AQP4-ab) presence is highly specific, and differentiates NMO from multiple sclerosis. It binds to AQP4 channels on astrocytes, triggering activation of the classical complement cascade, causing granulocyte, eosinophil, and lymphocyte infiltration, culminating in injury first to astrocyte, then oligodendrocytes followed by demyelination and neuronal loss. NMO spectrum disorder (NMOSD) has recently been defined and stratified based on AQP4-ab serology status. Most NMOSD patients experience severe relapses leading to permanent neurologic disability, making suppression of relapse frequency and severity, the primary objective in disease management. The most common treatments used for relapses are steroids and plasma exchange.Currently, long-term NMOSD relapse prevention includes off-label use of immunosuppressants, particularly rituximab.
Conclusions and future perspectives
During the last two decades, knowledge on the pathophysiological mechanisms involved in NMOSD has advanced significantly. In addition, new diagnostic features have been described, opening the door to new therapeutic targets. A clear demonstration of this, are the 3 new monoclonal antibodies, targeting 3 different disease pathways, showing efficacy in recent phase III-controlled trials [13, 19–21]. Although this has shifted broad immunosuppression to more narrow treatment targets, unmet needs persist in NMOSD patients.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
